Introduction Executive Summary P selectin inhibitors: Overview • Structure • Mechanism of Action Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment • Assessment by Product Type • Assessment by Stage and Product Type • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type P selectin inhibitors – DelveInsight’s Analytical Perspective In-depth Commercial Assessment • P selectin inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends P selectin inhibitors Collaboration Deals • Company-Company Collaborations (Licensing / Partnering) Analysis • Company-University Collaborations (Licensing / Partnering) Analysis Late Stage Products (Phase III) • Comparative Analysis DSTAT: Chimerix • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) • Comparative Analysis Crizanlizumab: Novartis • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Early Stage Products (Phase I) • Comparative Analysis Inclacumab: Global Blood Therapeutics • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Pre-clinical and Discovery Stage Products • Comparative Analysis Depolymerised holothurian glycosaminoglycan: Suzhou Ronnsi Pharma • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Inactive Products • Comparative Analysis P selectin inhibitors Key Companies P selectin inhibitors Key Products P selectin inhibitors- Unmet Needs P selectin inhibitors- Market Drivers and Barriers P selectin inhibitors- Future Perspectives and Conclusion P selectin inhibitors Analyst Views P selectin inhibitors Key Companies Appendix

Table 1 Total Products for P selectin inhibitors Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• Chimerix • Novartis • GlycoMimetics • Modus Therapeutics • Global Blood Therapeutics • Suzhou Ronnsi Pharma